Fig. S1. Recurrence-free survival curves according to histology, grade, and intrinsic subtype are shown in the training and validation cohort of patient samples.

Fig. S2. Immunostaining for E-cadherin and claudin-4.

Fig. S3. Kaplan–Meier graphs showing the simplified tight junction signature’s performance in the prediction of relapse-free, overall, and distant metastasis-free survival.

Fig. S4. Hierarchical clustering showing the contribution of the investigated proteins to the delineation of breast cancer cohorts.

Fig. S5. Kaplan–Meier graphs of the groups defined by the expression (below and above median) of evaluated claudin and E-cadherin proteins, individually.

Fig. S6. Performance of the claudin-4 and E-cadherin score on Kaplan–Meier graphs in the breast cancer groups with different oncological treatment.

CAS_2085_sm_FigS1.pdf335KSupporting info item
CAS_2085_sm_FigS2.pdf12765KSupporting info item
CAS_2085_sm_FigS3.pdf726KSupporting info item
CAS_2085_sm_FigS4.pdf1370KSupporting info item
CAS_2085_sm_FigS5.pdf1037KSupporting info item
CAS_2085_sm_FigS6.pdf318KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.